Keros Therapeutics, Inc. announced that its global development and commercialization license agreement with Takeda Pharmaceutical Company Limited for elritercept became effective on January 16, 2025. This formalizes the partnership previously announced in December 2024.
Under the terms of this agreement, Keros is set to receive a $200 million upfront cash payment, which was received in February 2025. The company is also eligible for potential development, commercial, and sales milestone payments that could exceed $1.1 billion, along with tiered royalties on net sales.
The agreement grants Takeda exclusive worldwide rights to further develop, manufacture, and commercialize elritercept in all indications and territories outside of mainland China, Hong Kong, and Macau. This partnership is expected to accelerate the development of elritercept for patients with myelodysplastic syndromes and myelofibrosis.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.